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Summary Hydroxylaminoglutethimide [3-ethyl-3-(4-hydroxylaminophenyl)piperidine-2, 6-dione] (HxAG),
aminoglutethimide [3-(4-aminophenyl)-3-ethylpiperidine-2, 6-dione] (AG) and N-acetyl-aminoglutethimide (N-
AcAG) have been quantified by high performance liquid chromatography using m-aminoglutethimide
(metaAG) as the internal standard in serial 24h urine collections from a patient on chronic AG therapy
without steroid supplementation. HxAG is the product of a major AG-induced metabolic pathway since the
ratio [HxAG]/[AG] rises with time. In contrast the ratio [N-AcAG]/[AG] decreases with time. A rapid, simple
colorimetric assay has been used to quantify HxAG in urine from both male and female patients receiving a
range of doses of AG and to show that induced metabolism is a general phenomenon even at low doses
(125 mg twice daily). AG therapy is known to alter the metabolic rate and plasma half-life of a number of co-
administered compounds including dexamethasone and warfarin. Clinicians should remain alerted to this
phenomenon.
We previously reported on the identification of
hydroxylamino-glutethimide [3-ethyl-3-(4-hydroxyl-
aminophenyl)piperidine-2, 6-dione] (HxAG), the
product ofinduced metabolism ofaminoglutethimide
[3-(4-aminophenyl)-3-ethylpiperidine-2, 6-dione]
(AG), in the urine of patients on chronic AG
therapy (Jarman et al., 1983). In the present study
our aim was to quantify HxAG, to confirm that
induction is AG-induced and increases with the
duration of therapy and to investigate its
dependence on the dose of AG. Furthermore we
were interested in whether induction correlates with
acetylator status or is a general phenomenon.
We report here on the quantification using high
performance liquid chromatography (HPLC) of
HxAG in serial 24h urine collections from a patient
receiving chronic AG therapy without steriod
supplementation. In addition we have used a rapid,
simple colorimetric assay to screen the urine of
both male and female patients on chronic AG
therapy for the presence of the induced metabolite.
Materials and methods
Quantification ofHxAG, AG and N-AcAG using
HPLC
A calibration curve was constructed as follows.
Mixtures of m-aminoglutethimide [3-(3-amino-
phenyl)-3-ethylpiperidine-2, 6-dione] (metaAG)
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(internal standard: 1 mg, solution in ethanol)
togther with HxAG (solution in acetone; Jarman et
al., 1983), AG and N-acetylaminoglutethimide (N-
AcAG) (solutions in ethanol, 200, 500, 1000, or
2000pg of each component) were concentrated to
dryness under a stream of nitrogen and the residues
redissolved in 10ml aliquots of pooled urine from
untreated post-menopausal volunteers. Each urine
was saturated with Na2HPO4 and extracted with
dichloromethane (10ml, pre-saturated with N2).
Each extract was dried (Na2SO4), concentrated, the
residues dissolved in acetonitrile and water (30:70,
200p1) and aliquots (3-4p1) subjected to reverse
phase HPLC on a Waters Model ALC/GPC 204
liquid chromatograph equipped with a Model
6000A solvent delivery system, a U6K injector, a
Model 440 dual channel absorbance detector
operated at 254 and 280 nm, and a p Bondapak C-
18 column (30cmx 3.9mm i.d.). The column was
eluted with the same solvent (1.5mlmin-1). Peak
heights for HxAG (retention time T=3.9min), AG
(T=5.5min) and metaAG (T=5.65min) were
measured and 3 linear regression calibration curves
constructed according to the formula:
[HxAG] or [AG] or [N-AcAG] vs
A254HxAG or AG or N-AcAG
A254 metaAG
Serial 24h urine collections were taken from one
patient (M.C.) at days 1, 2 and 8 and at 5 weeks
after the start of treatment (500mg AG daily p.o.)
without steroid supplementation. Following the
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method outlined above, aliquots of urine (10ml)
from these collections were assayed for HxAG, AG
and N-AcAG.
Quantification ofHxAG and screeningfor its
presence in patients' urine using colorimetry.
The assay was adapted from a general method
developed for the colorimetric determination ofaryl-
hydroxylamines (Boyland & Nery, 1964), and based
on the formation of a purple Baudisch complex
([Fe"(CN)5, RNO]3-) by reaction with sodium
amminepentacyanoferrate [Na3Fe(CN)5NH3. 6H201
(S.A.P.). Spectrophotometric determinations were
carried out using a Pye Unicam SP8-150 spectro-
photometer operated at 530 nm, the absorption
maximum ofthe purple chromophore formed. Water
(1 ml) and urine (1 ml) was used as the control in
the blank beam. A calibration curve was
constructed by reacting aliquots (1 ml) of blank
urine containing varying concentrations of HxAG
with S.A.P. (1 ml; 0.1% w/v in water) and plotting
the absorbance readings at fixed time intervals
against the concentration of HxAG. The intensity
of the chromophore formed reached a maximum
after 16h and this time was used for determining
the absorbances of subsequent samples.
Urine was collected from 80 patients and tested
for HxAG. Fifty patients were post-menopausal
women with metastatic breast cancer on chronic
AG treatment, the dose ranging from 500-1000mg
daily plus steroid supplementation. Only in the case
of the limited number of in-patients available was it
possible to obtain reliable 24h collections. A
"spot" urine sample was taken from 45 out-patients
and a 24h collection from 5 in-patients, who had
been receiving AG for more than 3 weeks. Spot
urine samples were collected from a further 20 out-
patients on low dose AG (125mg twice daily)
without steroid supplementation and from 10 male
out-patients being treated for metastatic prostatic
cancer. Aliquots of all samples including the serial
24h collections from patient M.C. mentioned
previously were assayed colorimetrically as outlined
above. Aliquots of control urine taken from
laboratory volunteers and patients with breast
cancer on alternative hormone and chemotherapy
were also tested.
Results
As reported previously (Jarman et al., 1983) HxAG
is highly unstable at room temperature oxidizing
readily to nitrosoglutethimide. This effect was most
marked for low concentrations of HxAG. Thus,
whereas linear regression calibration curves for
both AG and N-AcAG were reproducible, those for
HxAG showed a decreasing slope and increasing Y
intercept with time. Consequently, at low u.v.
absorbance readings spuriously high levels of
HxAG were obtained. Table I shows the results for
patient M.C. at days 1, 2, 8, 14 and 5 weeks obtained
by HPLC and by colorimetry and shows that
HxAG is an induced metabolite, the ratio of its
concentration to that of AG increasing with time.
Figure 1 compares the HPLC traces of extracts
taken at Day 1 and Day 14. HxAG was not
detectable on Day 1 but was abundant in the day
14 extract. Also the decrease in the concentration of
N-AcAG with time relative to AG, noted in our
previous study is clearly illustrated (see also Table
I). In the 5 further patients from whom 24h urine
collections were taken the percentage of the oral
dose excreted as the induced metabolite, determined
colorimetrically, was respectively 6, 11, 12, 36 and
44%.
All "spot" urine samples taken from patients on
treatment were positive colorimetrically for the
presence of the induced metabolite with a wide
variation in the concentration ranging from 5-
540,ugml- 1 (Figure 2). None of the aliquots of
control urine tested with S.A.P. gave a false
positive result.
Table I Quantities of aminoglutethimide (AG), N-acetylaminoglutethimide (N-AcAG)
and hydroxylaminoglutethimide (HxAG) excreted in the urine during 24h by a patient
(M.C.) given oral AG (500mg daily).
HxAG AG N-AcAG
mg/24h urine mg/24h urine mg/24h urine N-AcAG/AG HxAG/AG
Day HPLC Colorimetry HPLC HPLC x 100 x 100
1 9 1 1 53 31 58 16.5
2 12 10 42 19 45 28
8 62 57 200 60 30 31
14 45 39 126 34 26 35
35 126 120 210 46 22 60METABOLISM OF AMINOGLUTETHIMIDE IN HUMANS 261
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Figure 1 HPLC profiles of the organic extracts from
the 24h urine collections of a patient (M.C.) receiving
aminoglutethimide (500mg daily): taken at (a) Day 1
and (b) Day 14.
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Figure 2 Concentration of hydroxylamino-
glutethimide (HxAG), determined colorimetrically, in
urine samples from patients undergoing daily therapy
(dose in parentheses) with aminoglutethimide (AG).
Duration of treatment prior to sampling not less than
3 weeks.
Discussion
AG is a major form of endocrine therapy in post-
menopausal women with metastatic breast cancer.
Current evidence suggests that it acts by inhibiting
the formation of oestradiol from steroid precursors,
principally by retarding the conversion of
cholesterol into pregnenolone (by the enzyme
complex desmolase) and the aromatization of
androgens to oestrogens (by the enzyme complex
aromatase). Extension of its use as an adjuvant to
primary breast surgery (Coombes et al., 1982) as
well as in combination endocrine therapy (Powles
et al., 1982) is currently being investigated. Our
present interest in the metabolism of AG and its
possible influence on the therapeutic activity of the
drug was prompted in part by an earlier finding
(Murray et al., 1979) that the plasma half-life of
AG fell from a mean value of 13.2h to 7.3h in 6
patients after 3-5 weeks of daily treatment. We
previously reported on the identification of HxAG
as an induced metabolite, the formation of which
could account for this fall in plasma half-life
(Jarman et al., 1983). We have now quantified
HxAG by HPLC using metaAG as an internal
standard and have used this assay to monitor in
detail the time course of urinary excretion of AG
and its metabolite HxAG and N-AcAG in a patient
on chronic therapy. The assay is made difficult,
however, by rapid oxidation of HxAG to
nitrosoglutethimide and is inconvenient for routine
use. Therefore we have adapted the rapid, simple
colorimetric assay of Boyland & Nery (1964) for
routine use. The results from both methods
correlate closely (Table I). The results from the
time-course study on patient M.C. show that
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metabolism of AG to HxAG is an induced, major
metabolic pathway. Moreover despite a fall in
plasma half-life of AG in patients on chronic
therapy a mean plasma half-life of 7.3h implies
gradual accumulation of the drug in plasma and
consequently an increase in excretion of both the
parent compound and its metabolites. This effect
will ultimately plateau and the ratio of parent
compound to metabolites excreted in 24h becomes
a relevant reflection of metabolism. Thus the ratio
between the concentrations of HxAG and AG in
urine increases with time whereas the converse is
true for the metabolite N-AcAG. The unlikely
possibility that induction is due to hydrocortisone is
discounted by the presence of HxAG in the urine of
patients on AG without steroid supplementation.
We have previously shown that acetylation of
AG is genetically determined, the fast and slow
acetylator phenotype (Coombes et al., 1982) being
represented equally in volunteers. However induced
metabolism is general, since HxAG was detected in
all the patients' urines after chronic therapy.
Although it takes 16h for the intensity of the
purple chromophore formed by reacting HxAG
with S.A.P. to reach its maximun, a visible colour
change nevertheless occurs within minutes of
starting the reaction. Because of this, and because
of the apparent specificity of the colorimetric assay
for arylhydroxylamines and the nitroso-derivatives
formed from them by spontaneous oxidation
(Boyland & Nery, 1964) it can easily be used as a
bedside or out-patient procedure for assessing
patient's compliances to AG therapy.
The percentage inhibition of desmolase (inhibitor
concentration 50 gml-1) and aromatase
(20pgml-1) by AG and HxAG was respectively 85
and 90%, and 53 and 36% (Chohan et al., 1982).
HxAG therefore represents an inactivation product
of AG. Despite the fact that AG-induced
metabolism with a consequent fall in plasma half-
life occurs in patients on chronic AG therapy,
response rates are nevertheless comparable to those
from others forms of endocrine therapy. However,
AG can also induce the metabolism of other drugs
with which it is co-administered and diminish their
pharmacological effects as is the case with
dexamethasone (Santen et al., 1977) and warfarin
(Lonning et al., 1984). Since self-induced
metabolism of AG is general it is likely that this
effect of AG on the metabolism of other drugs will
be general also. Clinicians should therefore remain
alerted to the alteration in metabolic rate and
plasma half-life of a number of important co-
administered drugs in patients on chronic AG
therapy.
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